Litigation Details for GALDERMA LABORATORIES, L.P. v. TARO PHARMACEUTICALS INC. (D.N.J. 2024)

GALDERMA LABORATORIES, L.P. v. TARO PHARMACEUTICALS INC. (D.N.J. 2024)

Docket		Date Filed	2024-01-19
Court	District Court, D. New Jersey	Date Terminated	2024-07-08
Cause	35:271 Patent Infringement	Assigned To	Michael Andre Shipp
Jury Demand	None	Referred To	Tonianne J. Bongiovanni
Patents	9,084,778; 9,498,465
Attorneys	CHARLES H. CHEVALIER
Link to Docket	External link to docket

Details for GALDERMA LABORATORIES, L.P. v. TARO PHARMACEUTICALS INC. (D.N.J. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-01-19				External link to document

Galderma Laboratories v. Taro Pharmaceuticals Patent Litigation: Case No. 3:24-cv-00333

Last updated: September 27, 2026

Galderma Laboratories, L.P. sued Taro Pharmaceuticals Inc. in the U.S. District Court for the District of New Jersey after Taro submitted an Abbreviated New Drug Application seeking approval for a generic version of Galderma's Aklief, a trifarotene 0.005% topical cream used to treat acne vulgaris. The case is a Hatch-Waxman patent dispute based on Taro's Paragraph IV certification.

The litigation could delay FDA approval of Taro's product for up to 30 months from the date Galderma received notice of the Paragraph IV certification, unless the court resolves the case earlier or the parties settle. The commercial risk centers on whether Galderma can enforce its later-expiring formulation and method-of-use patents against Taro's proposed generic.

What drug is at issue in Galderma v. Taro?

The dispute concerns Aklief, whose active ingredient is trifarotene. Aklief is a topical retinoid indicated for the topical treatment of acne vulgaris in patients nine years of age and older.

Product	Active ingredient	Dosage form	Strength	Reference sponsor
Aklief	Trifarotene	Topical cream	0.005%	Galderma Laboratories, L.P.
Taro proposed product	Trifarotene	Topical cream	0.005%	Taro Pharmaceuticals Inc.

Aklief was approved by the FDA in 2019. It is a non-systemic dermatology product, so the principal barriers to generic entry are formulation patents, manufacturing controls, FDA approval requirements, and any enforceable method-of-use claims rather than biologic interchangeability rules.

What is trifarotene?

Trifarotene is a selective retinoic acid receptor gamma agonist. Aklief was developed for acne affecting the face and trunk. The product's intellectual-property position may cover the active ingredient, topical formulation, treatment regimen, and use in specified patient populations.

What is the procedural history of Case No. 3:24-cv-00333?

Galderma filed the action in the District of New Jersey after receiving Taro's Paragraph IV notice. Taro's ANDA filing gave Galderma the statutory basis to sue before FDA approval of the proposed generic.

Event	Significance
Taro submitted an ANDA	Taro sought FDA approval for a generic trifarotene cream
Taro filed a Paragraph IV certification	Taro asserted that listed Aklief patents were invalid, unenforceable, or would not be infringed
Galderma filed the complaint	The ANDA submission created an artificial act of infringement under 35 U.S.C. § 271(e)(2)
FDA approval timing	The litigation may trigger a 30-month stay under 21 U.S.C. § 355(j)(5)(B)(iii)
District court litigation	The court will address claim construction, infringement, validity, and possible equitable defenses

The case is a pharmaceutical patent action rather than a conventional commercial infringement dispute. Taro's product generally will not be sold while the case remains subject to the statutory stay, unless the stay expires or is shortened.

What patents protect Aklief and trifarotene cream?

Aklief's protection comes from a combination of Orange Book-listed patents and potentially related patent families that may not all have the same expiration date.

Publicly available patent records associate Aklief and trifarotene with patent claims directed to:

• Trifarotene compositions;
• Topical creams containing trifarotene;
• Treatment of acne vulgaris;
• Application of trifarotene to the face and trunk;
• Concentration, vehicle, and excipient combinations;
• Dosing and administration methods.

The relevant patent estate is more important than the number of patents alone. A single valid formulation patent can delay generic entry if Taro's ANDA product falls within the asserted claims.

What formulation patents matter most?

Formulation claims are likely to be central because Aklief is a cream rather than a simple oral solid dosage form. The relevant technical issues may include:

• The concentration of trifarotene;
• The cream base and solvent system;
• Distribution of the active ingredient;
• Chemical stability;
• Particle size or dissolution characteristics;
• Preservatives and excipients;
• Manufacturing conditions;
• The product's topical performance profile.

Taro may argue that its proposed formulation uses materially different excipients or manufacturing parameters. Galderma may respond that the claims cover functional characteristics, broad formulation categories, or equivalent ingredients.

The strength of the formulation case will depend on claim construction and the actual ANDA description, which is generally reviewed under protective-order restrictions during litigation.

What method-of-use patents are relevant?

Method-of-use claims may cover treatment of acne vulgaris with trifarotene, including application to specific body areas or patient groups. Under the Hatch-Waxman framework, Taro can attempt to carve out patented uses through a section viii statement and a corresponding FDA labeling strategy.

A method-of-use dispute becomes more difficult for Taro if:

1. The proposed label still encourages the patented use;
2. The patented use is inseparable from the approved indication;
3. Galderma proves induced infringement based on the generic label;
4. The asserted claims cover the complete approved use rather than an optional sub-use.

Taro's Paragraph IV strategy therefore may rely on invalidity, noninfringement, or a label carve-out, depending on the specific patents and approved labeling.

How does a Paragraph IV challenge affect generic entry?

A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. Filing the certification is treated as a technical act of infringement, allowing the patent owner to sue before commercial launch.

If the patent owner files within 45 days after receiving notice, FDA approval generally is subject to a 30-month stay. The stay can end earlier if:

• The court enters a final judgment of noninfringement or invalidity;
• The court orders a different date;
• The patent expires;
• The parties settle;
• The stay is forfeited under the Hatch-Waxman statute.

The first applicant with a qualifying Paragraph IV certification may receive 180 days of generic exclusivity. The public case information does not establish that Taro is entitled to first-filer exclusivity. That issue depends on the ANDA filing sequence and any prior Paragraph IV applicants.

When could Taro launch a generic trifarotene cream?

Taro's launch date depends on the earliest controlling event among patent expiry, litigation outcome, settlement terms, or loss of the statutory stay.

Launch scenario	Commercial result
Galderma wins on all asserted claims	Taro generally cannot launch until the relevant patents expire
Taro wins on invalidity	FDA approval may proceed after the court judgment and regulatory processing
Taro wins on noninfringement	Launch may occur after the judgment and any remaining FDA requirements
Galderma and Taro settle	Entry date depends on the settlement agreement
Partial judgment	Taro may launch only if the remaining patents do not block the proposed product
Label carve-out accepted	Taro may launch with a restricted indication

A final judgment does not automatically guarantee immediate commercial launch. Taro would still need FDA approval, satisfactory manufacturing inspection results, final labeling, and resolution of any remaining patent or regulatory barriers.

What is the Orange Book status of Aklief?

Aklief is an FDA-approved prescription drug subject to Orange Book patent listing. The Orange Book identifies patents that the NDA holder represents as claiming the drug, its formulation, or an approved method of use.

Orange Book listing has three commercial effects:

1. It informs ANDA applicants which patents require certification.
2. It provides the basis for a Paragraph IV patent challenge.
3. It can create the statutory 30-month approval stay after timely litigation.

The Orange Book does not decide whether a listed patent is valid or infringed. Those issues are determined by the district court, subject to appellate review.

Patent expiration should be evaluated patent by patent. The latest-expiring patent is not automatically enforceable against every generic product because the scope of each patent claim and the ANDA formulation must be compared directly.

How strong is Galderma's patent estate for Aklief?

Galderma's position is strongest if the asserted patents cover the specific trifarotene cream described in Taro's ANDA and if the patents have substantial remaining terms. The estate is weaker if the patents depend on narrow limitations, use claims that can be carved out, or formulation features absent from Taro's product.

Strength indicators

• Aklief has a distinct active ingredient and topical formulation.
• Trifarotene is protected by more than one patent family.
• Formulation claims may create a product-specific barrier.
• A Paragraph IV filing gives Galderma an opportunity to litigate before generic launch.
• The product has an approved indication that may be difficult to remove from a generic label without reducing commercial value.

Vulnerability indicators

• Retinoid formulations may face obviousness challenges based on earlier topical retinoids.
• Narrow formulation claims can be avoided through excipient changes.
• Method-of-use claims may be vulnerable to section viii carve-outs.
• The patent estate may have different expiry dates, allowing partial entry.
• Taro can challenge written description, enablement, anticipation, obviousness, and indefiniteness.

The most important legal question is whether the asserted claims require a particular formulation architecture that Taro's ANDA actually uses. If the claims are broad enough to cover the product category, Galderma's infringement case strengthens. If the claims depend on precise excipient ratios or manufacturing steps, Taro may have more room to design around them.

What patent litigation issues will the court decide?

The case will likely involve the standard Hatch-Waxman issues:

Infringement

Galderma must show that the product described in Taro's ANDA would infringe one or more asserted claims. The court evaluates the ANDA and related technical documents rather than hypothetical post-launch conduct.

Claim construction

The parties may dispute terms describing:

• Cream composition;
• Trifarotene concentration;
• Topical application;
• Treatment of acne;
• Stability;
• Pharmaceutical acceptability;
• Specific formulation components.

Claim construction can determine whether the dispute turns on literal infringement or requires an equivalents analysis.

Validity

Taro may challenge the patents based on:

• Anticipation under 35 U.S.C. § 102;
• Obviousness under 35 U.S.C. § 103;
• Lack of written description;
• Lack of enablement;
• Indefiniteness;
• Double patenting;
• Patent-term or prosecution-related defenses.

Enforceability

Taro could assert inequitable conduct if it identifies material information withheld from the U.S. Patent and Trademark Office with the required intent. Such defenses are difficult to prove and require clear and convincing evidence.

Which companies are challenging Galderma's Aklief patents?

The available case identification establishes Taro as a challenger in Case No. 3:24-cv-00333. Other ANDA applicants may challenge Aklief patents in separate cases or may receive confidential settlements. A complete competitive assessment requires review of the current Orange Book, FDA ANDA activity, and federal docket filings for additional trifarotene applicants.

Potential competitors fall into four categories:

1. ANDA applicants seeking a direct generic launch;
2. Applicants relying on section viii labeling exclusions;
3. Contract manufacturers supplying generic trifarotene;
4. Other topical acne products competing without infringing Aklief patents.

The relevant competitive threat is not limited to a product labeled as trifarotene. Adapalene, tretinoin, tazarotene, benzoyl peroxide combinations, and other topical retinoids compete within the same acne-treatment market.

What litigation and settlement outcomes are possible?

No settlement terms should be assumed unless disclosed in a filed agreement, court order, or public company statement.

Common Hatch-Waxman outcomes include:

• Patent litigation through trial;
• Consent judgment delaying entry until an agreed date;
• Early entry before patent expiry;
• License-based entry;
• Authorized generic arrangements;
• Label restrictions;
• Withdrawal of the Paragraph IV challenge;
• Dismissal after FDA or patent developments.

A settlement can preserve Galderma's revenue while giving Taro a defined launch date. The commercial value of that date depends on whether other generics launch first and whether Aklief retains market exclusivity through prescribing loyalty, rebates, or clinical differentiation.

What revenue exposure does Galderma face?

A generic trifarotene cream would pressure Aklief through price erosion, payer substitution, pharmacy substitution, and reduced access to new patients. The degree of erosion depends on:

• Whether Taro is the first generic;
• The number of later ANDA approvals;
• Whether 180-day exclusivity applies;
• The breadth of Taro's label;
• Payer coverage and formulary placement;
• Galderma's rebates and patient-support programs;
• Physician switching behavior;
• The availability of competing retinoids.

A single generic usually causes less immediate erosion than multiple generic launches. Topical dermatology products can also experience slower substitution than oral tablets because physicians may distinguish formulations by tolerability, vehicle, irritation profile, and patient adherence.

Does biosimilar risk apply to Aklief?

No. Aklief is a small-molecule drug regulated through the ANDA pathway. It is not a biologic and does not face biosimilar competition under the Biologics Price Competition and Innovation Act.

The applicable competitive framework is generic-drug substitution under the Hatch-Waxman Act. The principal questions are patent scope, ANDA approval, labeling, manufacturing equivalence, and launch timing.

How does Aklief compare with other Galderma dermatology products?

Product	Active ingredient	Product type	Primary patent risk
Aklief	Trifarotene	Topical cream	Trifarotene formulation and use patents
Soolantra	Ivermectin	Topical cream	Formulation and rosacea method-of-use patents
Epiduo/Epiduo Forte	Adapalene and benzoyl peroxide	Topical gel	Older combination-product patents
Twyneo	Tretinoin and benzoyl peroxide	Topical cream	Combination formulation patents
Oracea	Doxycycline	Oral capsule	Composition, dosing, and method-of-use patents

Aklief's risk profile differs from older Galderma products because the active ingredient is newer and the product has a more concentrated patent estate around trifarotene-specific technology. Twyneo presents a closer formulation comparison because both products rely on topical retinoid delivery and combination or cream technology.

Key Takeaways

• Case No. 3:24-cv-00333 is a Hatch-Waxman patent action brought by Galderma against Taro.
• The dispute concerns Taro's proposed generic version of Aklief, trifarotene 0.005% cream.
• Taro's Paragraph IV certification triggered Galderma's pre-launch infringement action.
• A timely suit can impose a 30-month FDA approval stay.
• Formulation and method-of-use claims are likely to be central.
• Aklief is a small-molecule drug, so biosimilar rules do not apply.
• Taro's launch timing depends on claim scope, validity, litigation results, settlement terms, and FDA approval.
• Generic entry would expose Galderma to pricing and market-share pressure, with the impact determined by the number and timing of competing ANDA approvals.

FAQs

What is the drug in Galderma Laboratories v. Taro Pharmaceuticals?

The dispute concerns Aklief, a topical trifarotene 0.005% cream approved for acne vulgaris.

Is Taro seeking approval for a biosimilar to Aklief?

No. Taro is pursuing an ANDA for a generic small-molecule drug, not a biosimilar application.

Does the lawsuit automatically prevent Taro from filing its ANDA?

No. Taro may file the ANDA and certify against the patents. The lawsuit can delay FDA approval and commercial launch through the Hatch-Waxman 30-month stay.

Can Taro launch with a narrower label?

Potentially. A section viii carve-out may allow a generic applicant to omit a patented method of use, but the resulting label must avoid encouraging infringement and remain acceptable to the FDA.

What would make Galderma's Aklief patents commercially valuable?

The strongest patents are those that cover Taro's actual cream formulation or an approved use that cannot be removed from the generic label without undermining the product's marketability.

References

1. U.S. Food and Drug Administration. (2019). FDA approves new treatment for acne. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

3. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.

4. U.S. Code. 35 U.S.C. § 271(e)(2).

5. U.S. Code. 21 U.S.C. § 355(j)(5)(B)(iii).

6. U.S. District Court for the District of New Jersey. (2024). Galderma Laboratories, L.P. v. Taro Pharmaceuticals Inc., No. 3:24-cv-00333. Federal court docket.